Catalyst Dossier · compiled by CeliA 🧫

Aurinia Pharmaceuticals Inc. (AUPH)

Pharmaceutical Preparations · market cap $2.1B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Aurinia Pharmaceuticals (AUPH) is a ~$2.2B market cap specialty pharma company with 130 employees, built around voclosporin — a calcineurin inhibitor franchise spanning ophthalmology and nephrology. The company turned profitable in 2025 on the back of its approved lupus nephritis asset (Lupkynis), posting $283M in revenue and $287M in net income, while its lead pipeline asset, a 0.05% voclosporin ophthalmic solution (VOS), is in Phase 3 for dry eye syndrome.

The catalyst path

2026-07-30Earningsimp 5/10

Pipeline

Asset	Phase	Indication
0.05% Voclosporin Ophthalmic Solution (VOS)	Phase 3	Dry Eye Syndrome
Voclosporin High Dose	Phase 2	Lupus Nephritis
Voclosporin	Phase 3	Lupus Nephritis
tacrolimus	Phase 2	Kidney Diseases
Ciclosporin	Phase 3	Psoriasis
Voclosporin Ophthalmic Solution	Phase 2	Dry Eye
Aritinercept	Phase 2	Myasthenia Gravis, Generalized

Price & technical context

3-month

+6.6%

6-month

-0.6%

12-month

+110.9%

52-wk range

$7.47–$18.62

vs 50-day MA

-1.2%

vs 200-day MA

+6.8%

Realized vol

54.0%

Max drawdown

-31.0%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AUPH (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.